Murphy Keith reported grant involving 5,000 derivative units of Matinas BioPharma Holdings, Inc. at $0.00 for $0 on Nov 6, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
5,000Stock Option (right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
5,000Direct
Trade date
Nov 6, 2026Grant
Filed
Nov 6, 2026, 6:27 PM ET0-day reporting delay
Accession
0001493152-26-050556Code A · Transaction 395315
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MTNB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MTNB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 13, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.